SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced the approval of new inducement awards by the Compensation Committee of its Board of Directors on June 6, 2025. Under Acadia's 2024 Inducement Plan, 41 new employees have been granted non-qualified stock options to purchase 187,664 shares of common stock and 89,582 restricted stock units (RSUs). The stock options have an exercise price of $21.98 per share, aligned with the closing trading price on the grant date, and are set to vest over four years. The RSUs will also vest over a four-year period, with 50% vesting on the second anniversary of the grant date. These awards are contingent upon the employees' continued service with Acadia and are governed by the terms of the 2024 Inducement Plan and corresponding award agreements.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.